Credit Suisse Group (CS) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:CS • US2254011081

0.8858 USD
+0.01 (+0.99%)
At close: Jun 9, 2023
0.899 USD
+0.01 (+1.49%)
After Hours: 6/9/2023, 8:04:01 PM
Fundamental Rating

1

Overall CS gets a fundamental rating of 1 out of 10. We evaluated CS against 238 industry peers in the Capital Markets industry. CS may be in some trouble as it scores bad on both profitability and health. CS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CS has reported negative net income.
CS Yearly Net Income VS EBIT VS OCF VS FCFCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10B -10B 20B 30B

1.2 Ratios

  • CS has a Return On Assets of 1.00%. This is comparable to the rest of the industry: CS outperforms 48.02% of its industry peers.
  • CS has a better Return On Equity (10.01%) than 69.31% of its industry peers.
Industry RankSector Rank
ROA 1%
ROE 10.01%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CS Yearly ROA, ROE, ROICCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 5 -5 -10 -15

1.3 Margins

  • The Profit Margin of CS (18.68%) is better than 64.85% of its industry peers.
  • CS does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 18.68%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CS Yearly Profit, Operating, Gross MarginsCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -20 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, CS has more shares outstanding
  • Compared to 1 year ago, CS has a worse debt to assets ratio.
CS Yearly Shares OutstandingCS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B
CS Yearly Total Debt VS Total AssetsCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200B 400B 600B 800B

2.2 Solvency

  • A Debt/Equity ratio of 2.80 is on the high side and indicates that CS has dependencies on debt financing.
  • CS has a worse Debt to Equity ratio (2.80) than 84.65% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.8
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
CS Yearly LT Debt VS Equity VS FCFCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50B 100B 150B

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
CS Yearly Current Assets VS Current LiabilitesCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50B 100B 150B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • CS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -702.95%.
  • CS shows a strong growth in Revenue. In the last year, the Revenue has grown by 48.34%.
  • The Revenue has been decreasing by -6.52% on average over the past years.
EPS 1Y (TTM)-702.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-576.1%
Revenue 1Y (TTM)48.34%
Revenue growth 3Y-12.77%
Revenue growth 5Y-6.52%
Sales Q2Q%318.56%

3.2 Future

  • CS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.46% yearly.
  • The Revenue is expected to grow by 2.57% on average over the next years.
EPS Next Y82.2%
EPS Next 2Y39.87%
EPS Next 3Y27.69%
EPS Next 5Y16.46%
Revenue Next Year-4.81%
Revenue Next 2Y-0.32%
Revenue Next 3Y0.61%
Revenue Next 5Y2.57%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CS Yearly Revenue VS EstimatesCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B 25B
CS Yearly EPS VS EstimatesCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CS Price Earnings VS Forward Price EarningsCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CS Per share dataCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CS's earnings are expected to grow with 27.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3Y27.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

Credit Suisse Group

NYSE:CS (6/9/2023, 8:04:01 PM)

After market: 0.899 +0.01 (+1.49%)

0.8858

+0.01 (+0.99%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)04-24
Earnings (Next)07-27
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.50B
Revenue(TTM)28.98B
Net Income(TTM)5.41B
Analysts46.09
Price Target1.51 (70.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-126.63%
Min EPS beat(2)-230.24%
Max EPS beat(2)-23.02%
EPS beat(4)0
Avg EPS beat(4)-3226.79%
Min EPS beat(4)-11871.5%
Max EPS beat(4)-23.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)174.77%
Min Revenue beat(2)-4.76%
Max Revenue beat(2)354.29%
Revenue beat(4)1
Avg Revenue beat(4)84.46%
Min Revenue beat(4)-9.84%
Max Revenue beat(4)354.29%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.18%
PT rev (3m)-56.39%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-45.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB 0.06
EV/EBITDA N/A
EPS(TTM)-3.58
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.24
BVpS15.38
TBVpS14.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1%
ROE 10.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 18.68%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 2.8
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)72.35%
Cap/Depr(5y)87.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-702.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-576.1%
EPS Next Y82.2%
EPS Next 2Y39.87%
EPS Next 3Y27.69%
EPS Next 5Y16.46%
Revenue 1Y (TTM)48.34%
Revenue growth 3Y-12.77%
Revenue growth 5Y-6.52%
Sales Q2Q%318.56%
Revenue Next Year-4.81%
Revenue Next 2Y-0.32%
Revenue Next 3Y0.61%
Revenue Next 5Y2.57%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.83%
EBIT Next 3Y24.95%
EBIT Next 5YN/A
FCF growth 1Y-65.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.59%
OCF growth 3YN/A
OCF growth 5YN/A

Credit Suisse Group / CS FAQ

What is the ChartMill fundamental rating of Credit Suisse Group (CS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CS.


What is the valuation status of Credit Suisse Group (CS) stock?

ChartMill assigns a valuation rating of 3 / 10 to Credit Suisse Group (CS). This can be considered as Overvalued.


What is the profitability of CS stock?

Credit Suisse Group (CS) has a profitability rating of 2 / 10.


Can you provide the financial health for CS stock?

The financial health rating of Credit Suisse Group (CS) is 0 / 10.